Clinical trial
A Protocol to Assess the Safety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Administration of Low-dose Lenalidomide (STAR-LLD) for the Treatment of Multiple Myeloma (MM)
NCT06087653 is registered in ClinicalTrials.gov with Starton Therapeutics, Inc as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Protocol to Assess the Safety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Administration of Low-dose Lenalidomide (STAR-LLD) for the Treatment of Multiple Myeloma (MM)
- Lead sponsor
- Starton Therapeutics, Inc
- Phase
- Phase 1/2
- Overall status
- Recruiting
- Start date
- October 2, 2023
- Completion date
- March 31, 2028
- Enrollment
- 24 (estimated)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.